Please take note of the following information:

Indications: Tirzepatide is used along with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus.

Contraindications: Do not use Tirzepatide if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). It should also not be used if you have a history of severe gastrointestinal disease, including gastroparesis.

Warnings and Precautions:

Thyroid C-Cell Tumors: Patients should be evaluated for risk factors before starting Tirzepatide and monitored for signs and symptoms of thyroid tumors.

Pancreatitis: Symptoms of pancreatitis should be reported immediately, as it can be serious.

Hypoglycemia with Concomitant Use of Insulin and Insulin Secretagogues: The risk of low blood sugar is higher when using Tirzepatide with insulin or insulin secretagogues.

Acute Kidney Injury: Patients, especially those with existing kidney problems, should be monitored for changes in kidney function.

Hypersensitivity Reactions: Serious allergic reactions have been reported with Tirzepatide. Tirzepatide should be stopped if a reaction occurs, and medical treatment should be sought.

Gastrointestinal Adverse Reactions: Nausea, vomiting, diarrhea, and constipation may occur, especially at the beginning of treatment.

Adverse Reactions: The most common adverse reactions associated with Tirzepatide include nausea, vomiting, diarrhea, abdominal pain, and constipation.

Pregnancy and Lactation: Tirzepatide should not be used during pregnancy as it may harm the fetus. It is unknown whether Tirzepatide is excreted in human milk, and caution should be exercised when administering Tirzepatide to breastfeeding women.

Drug Interactions: Be cautious when using Tirzepatide with other drugs that affect gastrointestinal motility or absorption, as well as drugs that may increase the risk of low blood sugar.

Patient Counseling Information: Patients should be educated about the risks and benefits of Tirzepatide therapy, including potential gastrointestinal reactions and low blood sugar. They should also be informed about the signs and symptoms of thyroid tumors, pancreatitis, and allergic reactions.

For more information on Tirzepatide safety and effectiveness, please visit HERE